HUL receives ₹1,560 crore tax demand for FY22, plans appeal | Quick Digest
Hindustan Unilever (HUL) has received an income tax assessment order of ₹1,559.69 crore for the financial year 2021-22. The demand includes transfer pricing adjustments and corporate tax disallowances. HUL plans to appeal the order, stating it expects no material impact on its operations or financials.
HUL received an income tax demand of ₹1,559.69 crore.
The demand is for the financial year 2021-22 (AY 2022-23).
It relates to transfer pricing adjustments and tax disallowances.
The notice was issued by the Assistant Commissioner of Income Tax, Mumbai.
HUL asserts no material impact on financials or business operations.
The company intends to file an appeal against the tax order.
Hindustan Unilever Limited (HUL), a prominent fast-moving consumer goods (FMCG) company in India, has received an income tax assessment order amounting to ₹1,559.69 crore. The demand pertains to the financial year 2021-22, corresponding to the assessment year 2022-23. The notice, received on January 7, 2026, from the Assistant Commissioner of Income Tax, Central Circle 5(2), Mumbai, primarily includes transfer pricing adjustments and certain corporate tax disallowances proposed by the tax authorities.
Despite the significant sum, HUL has clarified in its exchange filings that the assessment order is not expected to have any material impact on its financial position, operational performance, or ongoing business activities. The company also confirmed that no penalties, sanctions, or restrictions have been imposed as part of this order.
HUL plans to challenge the assessment by filing an appeal with the appropriate appellate authority within the prescribed timeline under the Income Tax Act. The company's management has expressed confidence in its legal position, stating that based on available judicial precedents, the demand raised should not affect its long-term fundamentals. This tax demand is one of multiple notices HUL has received recently, including a ₹962.75 crore demand in August 2024 related to TDS on the acquisition of GlaxoSmithKline Consumer Healthcare's intellectual property rights. Another demand of ₹1,986.25 crore for FY 2020-21 was also reported around October 2025. However, the current news specifically focuses on the ₹1,559.69 crore demand for FY22.
Read the full story on Quick Digest